Research record

Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.

Randomized human study published by The lancet. Diabetes & endocrinology, indexed because it matched monitored longevity research terms. Inclusion in this index does not establish that an intervention is effective or safe.

Plain-language guide

Five questions to ask about this record

What this is
randomized-human record from The lancet. Diabetes & endocrinology.
Why it may matter
It matched a longevity topic and may show how that evidence area is developing.
Evidence
Automated topic match 100%; this is not a medical rating.
Main limitation
One research record does not prove safety, effectiveness, or usefulness for an individual.
What changed
Source metadata was published or refreshed August 22, 2025.
Where to verify
Open the primary source below for methods, population, results, and limitations.
Published
August 22, 2025
Journal
The lancet. Diabetes & endocrinology
Authors
Yang He, Nianrong Mi, Zhifeng Cheng, Haibo Xue, Jie Han, Haifang Wang, Huihui Wang, Jun Wu, Xiaoguang Shi, Shuping Zhao, Binhong Duan, Yikun Zhu, Yanqin Zhou, Feng Li, Xin Wang, Hongwei Ling, Su Wang, Qingju Li, Feifei Jiang, Ming Yang, Shaohui Bing, Qing Zheng, Jing Ning, Mengying Guo, Yue Bu, Lei Guan, Yao Li, Liu Yang, Wanjun Guo, Hai Pan
DOI
10.1016/S2213-8587(25)00196-2
Evidence class
randomized-human
Record status
published
Match confidence
100%
Source feed
PubMed
Automated source synopsis

Randomized human study published by The lancet. Diabetes & endocrinology, indexed because it matched monitored longevity research terms. Inclusion in this index does not establish that an intervention is effective or safe.

Evidence snapshot

What the source actually supports

Evidence stage
Randomized human study
Study design
Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III; Equivalence Trial; Research Support, Non-U.S. Gov't
Evidence population
Human evidence
Participants
Not reported
Population
Not reported
Duration
Not reported
Intervention
Comparator
Not reported
Outcomes measured
Reported result
No reusable finding-level result is available in this record.

Main limitationBibliographic metadata identifies the record but does not provide enough reusable detail to summarize its population, comparison, findings, or effect size.

Safety and approvalThis index record does not establish safety, effectiveness, dose, or suitability for any person. A publication record is not a regulatory approval or treatment recommendation.

Source supportBibliographic citation metadata and controlled indexing terms only. Read the linked source for methods and results.

Evidence stage · randomized-humanThis describes the study type, not whether an intervention is safe or effective.
Lab or animalHuman studyRandomized trialEvidence synthesis
Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Metformin · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term.

Automated source check 95% · update recency 65%. These figures help sort records; they are not medical ratings.

BibTeX · RIS

metformin
Read the original source →Export JSON